Study: Heart Attack Outcomes Far Worse for Those With COVID-19

New Research From the Smidt Heart Institute Shows That Heart Attack Patients Who Also Had COVID-19 Were Three Times More Likely to Die in the Hospital

New research from the Smidt Heart Institute at Cedars-Sinai shows that patients who went to a hospital with a heart attack and were simultaneously sick with COVID-19 were three times more likely to die than patients experiencing a heart attack without a COVID-19 infection.

The study published in the peer-reviewed journal Current Problems in Cardiology-also found that the Black, Hispanic, Asian, and Pacific Islander patients who had both COVID-19 and acute myocardial infarction (AMI)-the medical term for a heart attack-fared worse than their white counterparts.

“The COVID-19 pandemic had a significant impact on heart attack patients and disrupted optimal care that led to delays and changes in traditional, often lifesaving treatment approaches,” said Martha Gulati, MD, director of Preventive Cardiology in the Smidt Heart Institute and the study’s senior author. “Most importantly, we found significant racial disparities in the management of AMI in patients with concurrent COVID-19, with Black, Hispanic, Asian, and Pacific Islander patients receiving lower rates of treatment when compared to white patients.”

Gulati, the Anita Dann Friedman Endowed Chair in Women’s Cardiovascular Medicine and Research and the associate director of the Barbra Streisand Women’s Heart Center, said these findings point to the urgent need to address disparities and enhance access to care.

As investigators explain, the COVID-19 pandemic put a spotlight on gaps in cardiovascular care that already existed based on race and ethnicity. Addressing these disparities in healthcare urgently requires a multifaceted approach.

“While this study provides valuable insight, it is one piece of the puzzle,” said Christine M. Albert, MD, MPH, chair of the Department of Cardiology in the Smidt Heart Institute. “Addressing healthcare disparities, particularly during a global pandemic, requires a concerted effort from all stakeholders, including policymakers, healthcare providers, and the community at large.”

The Cedars-Sinai Newsroom sat down with Gulati to learn how the findings of this research study prompted ideas on addressing healthcare disparities and enhancing access to care:

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”